Australia markets closed

SNY Sep 2024 42.500 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.43000.0000 (0.00%)
As of 02:45PM EDT. Market open.
Full screen
Previous close0.4300
Open0.4300
Bid0.0000
Ask4.8000
Strike42.50
Expiry date2024-09-20
Day's range0.4300 - 0.4300
Contract rangeN/A
Volume1
Open interest508
  • Yahoo Finance Video

    Novavax shares skyrocket on $1.2 billion Sanofi vaccine deal

    Novavax (NVAX) shares are skyrocketing after announcing a $1.2 billion deal with Sanofi (SNY) to commercialize a combined COVID-19 and flu shot. Yahoo Finance's Anjalee Khemlani joins The Morning Brief to report more on the story. The Novavax-Sanofi deal also includes co-commercialization of the COVID-19 vaccine currently on the market. Novavax will be entitled to an additional $200 million for any new vaccines involving its adjuvant. Sanofi will receive a minority stake of less than 5% in Novavax and will invest $70 million. Shares of Novavax jumped more than 120% following the news. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Melanie Riehl

  • Yahoo Finance Video

    Stock markets, China tariffs, Novavax and Sanofi: 3 Things

    The major stock market indexes (^DJI, ^IXIC, ^GSPC) are on the road to closing out the first full trading week of May on a high note, alongside several of its European counterparts: the FTSE 100 (^FTSE), the DAX Performance Index (^GDAXI), and the CAC 40 (^FCHI). President Biden is reportedly set to announce updates on Trump-era trade tariffs on China. Novavax (NVAX) shares are skyrocketing over 110% on news of the biotech company's plans to licensing deal with Sanofi (SNY, SAN.PA) to co-commercialize its COVID-19 vaccine For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.

  • Bloomberg

    Novavax Soars on $1.2 Billion Sanofi Vaccine Licensing Deal

    (Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Most Read from BloombergBiden Set to Hit China EVs, Strategic Sectors With TariffsAckman Scolded Over DEI Views at Closed-Door Milken SessionApple Apologizes for iPad Pro Ad, Scraps Plan to Air It on TVNovavax Soars on $1.2 Billion Sanofi Vaccine Licensing DealMarjorie Taylor Greene Finally Got What She Deserved: DefeatN